• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Photocoagulator gets FDA marketing OK

Article

Santa Clara, CA—Lumenis Ltd. has received FDA clearance to market its Novus 3000, a 532 nm diode-pumped solid-state (DPSS) photocoagulator.

Santa Clara, CA-Lumenis Ltd. has received FDA clearance to market its Novus 3000, a 532 nm diode-pumped solid-state (DPSS) photocoagulator.

The new product is an improved version of its Novus 2000, which has about 1,500 units installed worldwide. The device offers up to 3 watts of power through semiconductor-based technology, and has a color touch-screen interface and liquid crystal display remote control for instant adjustments to treatment parameters. Novus 3000 features built-in storage for a laser indirect ophthalmoscope, remote control, foot switch, and other accessories.

Multiple memory locations allow ophthalmologists to save and recall preferences, and two dedicated illumination sources expand treatment options. Two delivery devices can be attached at once for switching during procedures.

Related Videos
Neda Nikpoor, MD, talks about the Light Adjustable Lens at ASCRS 2024
© 2024 MJH Life Sciences

All rights reserved.